Humacyte, Inc. (NASDAQ:HUMA) Director Sells $1,982,081.40 in Stock

Humacyte, Inc. (NASDAQ:HUMAGet Free Report) Director Brady W. Dougan sold 271,518 shares of Humacyte stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $7.30, for a total value of $1,982,081.40. Following the sale, the director now directly owns 4,559,140 shares of the company’s stock, valued at $33,281,722. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Humacyte Price Performance

HUMA traded down $0.14 during trading on Thursday, hitting $7.20. 1,301,550 shares of the stock traded hands, compared to its average volume of 1,558,718. The business has a 50 day moving average price of $5.29 and a 200 day moving average price of $3.93. The company has a debt-to-equity ratio of 0.61, a current ratio of 8.37 and a quick ratio of 8.37. Humacyte, Inc. has a twelve month low of $1.96 and a twelve month high of $9.97. The company has a market cap of $857.38 million, a price-to-earnings ratio of -7.20 and a beta of 1.62.

Humacyte (NASDAQ:HUMAGet Free Report) last announced its quarterly earnings data on Friday, May 10th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Equities research analysts forecast that Humacyte, Inc. will post -0.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on HUMA. Piper Sandler reissued a “neutral” rating and issued a $4.00 target price on shares of Humacyte in a research report on Tuesday, March 26th. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price objective on shares of Humacyte in a research note on Monday, April 1st. Finally, Benchmark reaffirmed a “buy” rating and issued a $15.00 price target on shares of Humacyte in a research note on Friday, May 24th.

Get Our Latest Stock Report on Humacyte

Institutional Investors Weigh In On Humacyte

Hedge funds have recently made changes to their positions in the stock. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in Humacyte in the 3rd quarter valued at approximately $53,000. Clough Capital Partners L P bought a new stake in shares of Humacyte during the third quarter worth $232,000. Rokos Capital Management LLP increased its holdings in shares of Humacyte by 122.5% during the third quarter. Rokos Capital Management LLP now owns 200,000 shares of the company’s stock worth $587,000 after buying an additional 110,097 shares in the last quarter. GSA Capital Partners LLP lifted its stake in shares of Humacyte by 139.5% in the 3rd quarter. GSA Capital Partners LLP now owns 355,918 shares of the company’s stock valued at $1,043,000 after acquiring an additional 207,333 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. acquired a new stake in shares of Humacyte during the 4th quarter valued at $28,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

About Humacyte

(Get Free Report)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

Read More

Insider Buying and Selling by Quarter for Humacyte (NASDAQ:HUMA)

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.